GSK chief Emma Walmsley sees pay raise amid 'landmark' year

Nicole DeFeudis

Editor

GSK chief Emma Walmsley saw a slight pay raise amid what she called a “landmark year” for the company, including the spinout of its consumer health unit Haleon.

The CEO took home roughly £8.45 million in 2022 (nearly $10.3 million), up from £8.2 million the year prior. That includes a £37,000 salary boost and an added £868,000 in bonus money compared to 2021, according to a recent report.

However, her pay package continues to lag behind other pharma chiefs, including fellow UK-based AstraZeneca CEO Pascal Soriot, whose pay package totaled £15.3 million (more than $18.6 million) in 2022. American pharma chiefs tend to take home heftier pay packages, such as AbbVie CEO Rick Gonzalez, who brought in $26.2 million.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

GSK chief Emma Walmsley sees pay raise amid 'landmark' year

Nicole DeFeudis

Editor

Unlock this article instantly by becoming a free subscriber.

J&J's AI head jumps to Recursion; Doug Williams resigns as Sana's R&D chief

Rare neuro disorder offers new area for competition, analysts say: #AAN24

CSL Vifor proposes a marketing campaign to settle European Commission investigation

Takeda wins label expansion for subcutaneous Entyvio, creating 'flexibility' for Crohn's patients

Senators want to know more on why Novo is discontinuing its insulin Levemir

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

GSK chief Em­ma Walm­s­ley sees pay raise amid 'land­mark' year

Nicole DeFeudis

Editor

Unlock this article instantly by becoming a free subscriber.

more like this

J&J's AI head jumps to Re­cur­sion; Doug Williams re­signs as Sana's R&D chief

Rare neu­ro dis­or­der of­fers new area for com­pe­ti­tion, an­a­lysts say: #AAN24

CSL Vi­for pro­pos­es a mar­ket­ing cam­paign to set­tle Eu­ro­pean Com­mis­sion in­ves­ti­ga­tion

Take­da wins la­bel ex­pan­sion for sub­cu­ta­neous En­tyvio, cre­at­ing 'flex­i­bil­i­ty' for Crohn's pa­tients

Sen­a­tors want to know more on why No­vo is dis­con­tin­u­ing its in­sulin Lev­emir

Ver­tex, Alpine’s IgAN drug has Hu­mi­ra-like po­ten­tial. But not all in­di­ca­tions are cre­at­ed equal

GSK chief Emma Walmsley sees pay raise amid 'landmark' year

J&J's AI head jumps to Recursion; Doug Williams resigns as Sana's R&D chief

Rare neuro disorder offers new area for competition, analysts say: #AAN24

CSL Vifor proposes a marketing campaign to settle European Commission investigation

Takeda wins label expansion for subcutaneous Entyvio, creating 'flexibility' for Crohn's patients

Senators want to know more on why Novo is discontinuing its insulin Levemir

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal